natgillin/translations-raw huggingface dataset:
Low inter (CV=21%) and intra (CV=12%) patient variability on busulfan exposure was demonstrated through a population pharmacokinetic analysis, performed on 102 patients.
Med farmakokinetično analizo, izvedeno pri 102 bolnikih, so znotraj populacije ugotovili nizko inter- (CV = 21 %) in intravariabilnost (CV = 12 %) bolnikov pri izpostavitvi busulfanu.
Respiratory: shortness of breath, nasal secretion (rhinitis), sore throat, cough, hiccup, nosebleeds, abnormal breath sounds.
Dihala: kratka sapa, izcedek iz nosu (rinitis), vneto grlo, kašelj, kolcanje, krvavitve iz nosu, neobičajni zvoki pri dihanju.
No evidence of an induction effect of phenytoin has been seen on busulfan data.
V podatkih o busulfanu ni bilo dokazov za indukcijski učinek fenitoina.
General: fever, headache, weakness, chills, pain, allergic reaction, oedema, general pain or inflammation at injection site, chest pain, inflammation of the mucosa.
Splošno: povišana telesna temperatura, glavobol, oslabelost, mrzlica, bolečina, alergijske reakcije, edem, bolečina ali vnetje na mestu vboda, bolečina v prsih, vnetje sluznic.
Haematuria Moderate renal insufficiency
Bolezni sečil disurija oligurija hematurija zmerna ledvična insuficienca
Similar blood exposure was observed when comparing plasma concentrations in adult patients receiving oral and intravenous busulfan at 1 mg/kg and 0.8 mg/kg respectively.
Med primerjavo plazemskih koncentracij po peroralni in intravenski uporabi busulfana, pri odraslih bolnikih (odmerek 1 mg/kg in 0,8 mg/kg) so opazili podobno prisotnost učinkovine v krvi.
Platelet engraftment occurred at a median of 9 (range, 1-16) days after allo-HCT.
Vsaditev trombocitov se je pojavila mediano 9 dni (razpon: od 1 do 16) po homologni transplantaciji hematopoetskih celic.
In children, thrombocytopenia (< 25x109/l or requiring platelet transfusion) occurred in 100% of patients.
Trombocitopenija (< 25 x 109/l ali zahtevana transfuzija trombocitov) se je pojavila pri 100 % bolnikov.
Arrhythmia Atrial fibrillation Cardiomegaly Pericardial effusion
Srčne bolezni tahikardija aritmija atrijska fibrilacija kardiomegalija perikardialni ventrikularna ekstrasistola bradikardija
Delirium Nervousness Hallucination Agitation
Psihiatrične motnje tesnoba depresija nespečnost zmedenost delirij živčnost halucinacije vznemirjenost
The use of paracetamol during the 72 hours prior to or with Busulfan Fresenius Kabi administration should be used with caution.
Bodite zelo previdni pri uporabi paracetamola 72 ur pred uporabo ali sočasno z uporabo zdravila Busulfan Fresenius Kabi.
To prepare the final solution for infusion, add (A) ml of Busulfan Fresenius Kabi to (B) ml of diluent (sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%)
Za pripravo končne raztopine za infundiranje dodajte (A) ml zdravila Busulfan Fresenius Kabi v (B) ml redčila (0,9 % raztopina natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopina glukoze za injiciranje).
Dimethylacetamide Macrogol 400
6.1 Seznam pomožnih snovi dimetilacetamid makrogol 400
A final concentration of approximately 0.5 mg/ml busulfan should be achieved.
Tako zagotovimo končno koncentracijo busulfana približno 0,5 mg/ml.
A continuous variation of clearance ranging from 2.49 to 3.92 ml/minute/kg has been established in children from < 6 months up to 17 years old.
Pri otrocih, starih manj od 6 mesecev do 17 let, so ugotovili stalno nihanje očistka v intervalu med 2,49 in 3,92 ml/min/kg.
Busulfan depleted oocytes of female rats, and induced sterility in male rats and hamster.
Busulfan je pri samicah podgan uničil oocite; pri samcih podgan in hrčkov pa je povzročil neplodnost.
After dilution: one ml of solution contains approximately 0.5 mg of busulfan.
Po redčenju: 1 ml raztopine vsebuje približno 0,5 mg busulfana.
There is limited clinical experience of the use of busulfan as a component of a conditioning regimen prior to HSCT in children with Fanconi's anaemia.
Ni zadostnih kliničnih izkušenj z uporabo busulfana kot komponente pri pripravljalnem zdravljenju pred presajanjem hematopoetskih matičnih celic (HSCT), pri otrocih s Fanconijevo anemijo, zato je treba busulfan pri tej skupini bolnikov uporabljati previdno.
The effects of hepatic dysfunction on intravenous busulfan disposition have not been assessed.
Učinki okvare jeter na delovanje intravensko uporabljenega busulfana še niso bili ocenjeni.
Hepatic: enlarged liver, jaundice, blocking of a liver vein.
Jetra: povečanje jeter, zlatenica, zaprtje jetrne vene.
Either phenytoin or benzodiazepines were administered for seizure prophylaxis in patients participating to the clinical trials conducted with intravenous busulfan (see section 4.2 and 4.4).
Pri bolnikih, ki so sodelovali v kliničnih preskušanjih z intravensko uporabo busulfana, so za preprečevanje epileptičnih napadov uporabili fenitoin ali benzodiazepine (glejte poglavji 4.2 in 4.4).
How to use Busulfan Fresenius Kabi
Kako uporabljati zdravilo Busulfan Fresenius Kabi
Skin: rash, itching, loss of hairs.
Koža: izpuščaj, srbenje, izpadanje las.
Renal disorder
Razredčena raztopina
Calculation of the quantity of Busulfan Fresenius Kabi to be diluted and of the diluent Busulfan Fresenius Kabi must be diluted prior to use with either sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Izračun količine zdravila Busulfan Fresenius Kabi, ki ga morate razredčiti, in tekočine za redčenje Zdravilo Busulfan Fresenius Kabi je potrebno pred uporabo razredčiti z 0,9 % raztopino natrijevega klorida za injiciranje (9 mg/ml) ali s 5 % raztopino glukoze za injiciranje.
As with other cytotoxic compounds, caution should be exercised in handling and preparing the busulfan solution: - The use of gloves and protective clothing is recommended.
Kot pri vseh citotoksičnih spojinah, morate biti pri ravnanju z busulfanom in pri njegovi pripravi previdni:
Obese patients
Debeli bolniki
In this case infusion sets with minimal priming space should be used (i.e 0.3-0.6 ml), primed with medicinal product solution prior to beginning the actual busulfan infusion and then flushed with sodium chloride 9 mg/ml (0.9%) solution for injection or glucose (5%) solution for injection.
V tem primeru je treba uporabiti komplete za infundiranje z najmanjšim možnim volumnom za izpiranje (tj. 0,3-0,6 ml), pri katerih najprej sistem splaknemo z majhno količino busulfana pred dejanskim infundiranjem busulfana (izpiranje), in nato po končanem infundiranju sistem splaknemo z 0,9 % raztopino natrijevega klorida za injiciranje (9 mg/ml) ali s 5 % raztopino glukoze za injiciranje.
There is no known antidote to busulfan other than haematopoietic progenitor cell transplantation.
Razen transplantacije hematopoetskih progenitorskih celic ni znanega antidota za busulfan.
Busulfan Fresenius Kabi must be prepared by a healthcare professional using sterile transfer techniques.
Zdravilo Busulfan Fresenius Kabi mora pripraviti usposobljen zdravstveni delavec/delavka v sterilnih pogojih.
After dilution, 1 ml of solution for infusion contains 0.5 mg of busulfan.
Po redčenju 1 ml raztopine za infundiranje vsebuje 0,5 mg busulfana.
No interaction was observed when busulfan was combined with fluconazole (antifungal agent).
Pri zdravljenju s kombinacijo busulfana in flukonazola (antimikotik) niso ugotovili medsebojnega delovanja.
Hepatic veno-occlusive disease is a major complication that can occur during treatment with busulfan.
Poglavitni zaplet, ki se lahko pojavi med zdravljenjem z busulfanom, je veno-okluzivna bolezen jeter.
Busulfan Fresenius Kabi must be diluted prior to administration.
Zdravilo Busulfan Fresenius Kabi je potrebno pred uporabo razredčiti.
Headache Nervous system disorders [Not Elsewhere Classified]
Bolezni živčevja glavobol, bolezni živčevja [nerazvrščene možganska krvavitev, encefalopatija drugje]
This medicine contains the active substance busulfan, which belongs to a group of medicines called alkylating agents.
Kaj je zdravilo Busulfan Fresenius Kabi in za kaj ga uporabljamo To zdravilo vsebuje aktivno učinkovino busulfan, ki spada v skupino zdravil, imenovanih alkilirajoče učinkovine.
Periodic monitoring of renal function should be considered during therapy with busulfan (see section
Med terapijo z busulfanom je potreben občasen nadzor ledvične funkcije (glejte poglavje 4.8).
Liver disorders.
Bolezni jeter.
Therefore, men treated with busulfan are advised not to father a child during and up to 6 months after treatment and to seek advice on cryo-conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with busulfan.
Priporočljivo je, da se moški pred zdravljenjem z busulfanom posvetujejo glede shranitve semena z zamrznitvijo, saj zaradi zdravljenja obstaja možnost trajne neplodnosti.
Hypoalbuminaemia Electrolyte disturbance Hyperglycaemia
Presnovne in prehranske motnje hipoalbuminemija, motnje elektrolitov, hiperglikemija anoreksija
Busulfan Fresenius Kabi must not be put into an intravenous bag that does not contain sodium chloride 9 mg/ml (0.9%) solution for injection or glucose solution for injection 5%.
Zdravila Busulfan Fresenius Kabi ne smete dati v intravensko vrečko, v kateri ni 0,9 % raztopine natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopine glukoze za injiciranje.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Busulfan Fresenius Kabi 6 mg/ml sterile concentrate busulfan
IME ZDRAVILA IN POT(I) UPORABE Busulfan Fresenius Kabi 6 mg/ml sterilen koncentrat busulfan intravenska uporaba po redčenju
PROCEDURE FOR PROPER DISPOSAL
PRIPOROČILA ZA VARNO RAVNANJE
A reduced incidence of Hepatic Veno Occlusive Disease (HVOD) and other regimen-related toxicity have been observed in patients when the lag time between the last dose of oral busulfan and the first dose of cyclophosphamide is > 24hours.
Pri bolnikih, kjer je bil čas zakasnitve med zadnjim peroralnim odmerkom busulfana in prvim odmerkom ciklofosfamida večji 24 ur, so opazili zmanjšano pojavnost veno-okluzivne bolezni jeter (Hepatic VenoOcclusive Disease - HVOD) in drugih toksičnosti, povezanih z njuno uporabo.
Infections and infestations
Infekcijske in parazitske bolezni:
NAME OF THE MEDICINAL PRODUCT Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion
IME ZDRAVILA Busulfan Fresenius Kabi 6 mg/ml koncentrat za raztopino za infundiranje
METHOD AND ROUTE OF ADMINISTRATION Read the package leaflet before use Intravenous use after dilution.
POSTOPEK IN POT(I) UPORABE ZDRAVILA Pred uporabo preberite priloženo navodilo!
Diluted Busulfan Fresenius Kabi is a clear colourless solution.
Razredčeno zdravilo Busulfan Fresenius Kabi je prozorna, brezbarvna raztopina.
Busulfan Fresenius Kabi in combination with fludarabine The recommended dose of busulfan is 3.2 mg/kg Each infusion will last 3 hours
Zdravilo Busulfan Fresenius Kabi v kombinaciji s fludarabinom - Priporočeni odmerek zdravila Busulfan Fresenius Kabi je 3,2 mg/kg.
Busulfan Fresenius Kabi 6 mg/ml concentrate for solution for infusion busulfan
Busulfan Fresenius Kabi 6 mg/ml koncentrat za raztopino za infundiranje busulfan
• Quantity of diluent: (A ml Busulfan Fresenius Kabi) x (10) = B ml of diluent To prepare the final solution for infusion, add (A) ml of Busulfan Fresenius Kabi to (B) ml of diluent
• Količina redčila: (A ml zdravila Busulfan Fresenius Kabi) x (10) = B ml redčila Za pripravo končne raztopine za infundiranje dodajte (A) ml zdravila Busulfan Fresenius Kabi v (B) ml redčila (0,9 % raztopina natrijevega klorida za injiciranje (9 mg/ml) ali 5 % raztopina glukoze za injiciranje).
STATEMENT OF ACTIVE SUBSTANCE One ml of concentrate contains 6 mg of busulfan and provides 0.5 mg/ml of busulfan after dilution
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN En ml koncentrata vsebuje 6 mg busulfana, po redčenju je koncentracija busulfana 0,5 mg/ml.
The median time to neutropenia was 4 days for both autologous and allogeneic patients.
Pri avtolognih in alogenskih bolnikih je bil mediani čas do nevtropenije 4 dni.
Femoral artery thrombosis Capillary leak
Žilne bolezni hipertenzija hipotenzija tromboza vazodilacija femoralna arterijska tromboza sindrom kapilarnega prepuščanja
Immune system disorders
Bolezni imunskega sistema:
How to store Busulfan Fresenius Kabi
Shranjevanje zdravila Busulfan Fresenius Kabi
If you get any side effects, talk to your doctor.
Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro.
GENERAL CLASSIFICATION FOR SUPPLY Medicinal product subject to restricted medical prescription.
NAČIN IZDAJANJA ZDRAVILA Predpisovanje in izdaja zdravila je le s posebnim režimom.
In adults The recommended dose and schedule of administration is:
Priporočeni odmerek in razpored uporabe busulfana:
Pulmonary haemorrhage
Žilne bolezni hipertenzija
• Quantity of Busulfan Fresenius Kabi: Y (kg) x D (mg/kg)
• Količina zdravila Busulfan Fresenius Kabi: (Y (kg) x D (mg/kg)) / (6 (mg/kg)) = A ml zdravila Busulfan Fresenius Kabi, ki ga morate redčiti Y: telesna masa bolnika v kilogramih
No age effect on busulfan clearance was evidenced from available intravenous busulfan data in patients over 60 years.
Glede na razpoložljive podatke o intravenski uporabi busulfana pri bolnikih, starejših od 60 let, starost ne vpliva na očistek busulfana.
Similar targeting rate is achieved within the daily exposure of 3600 - 6000 µmol/L.minute following the administration of intravenous busulfan 3.2 mg/kg once daily.
Podoben ciljni delež je bil dosežen z dnevno izpostavljenostjo od 3.600 do 6.000 µmol/l.
The terminal half life ranged from 2.26 to 2.52 h. Inter and intra patient variabilities in plasma exposure were lower than 20% and 10%, respectively.
Odstopanja pri izpostavljenosti v plazmi so bila med bolniki manjša od 20 %, pri posameznem bolniku pa manjša od 10 %.
Gastro-intestinal: nausea, inflammation of the mucosa of the mouth, vomiting, abdominal pain, diarrhoea, constipation, heart burn, anus discomfort, liquid in the abdomen.
Prebavila: slabost, vnetje ustne sluznice, bruhanje, bolečina v trebuhu, driska, zaprtje, zgaga, bolečine v zadnjiku, tekočina v trebuhu.
Agitation Confusional state Hallucination
Psihiatrične motnje agitiranost, stanje zmedenosti, halucinacije
For any information about this medicine, please contact the Marketing Authorisation Holder This leaflet was last revised in {MM/YYYY} Other sources of information
Za vse morebitne nadaljnje informacije o tem zdravilu se lahko obrnete na predstavništvo imetnika dovoljenja za promet z zdravilom.
Gastro-intestinal: inflammation of the mucosa of oesophagus, paralysis of the gut, vomiting blood.
Prebavila: vnetje sluznice požiralnika, paraliza črevesja, bruhanje krvi.
Adequate contraceptive precautions should be used when either partner is receiving Busulfan Fresenius Kabi.
Če kateri koli od partnerjev prejema zdravilo Busulfan Fresenius Kabi, morata poskrbeti za ustrezno kontracepcijo.
There is no common metabolism pathway between busulfan and fludarabine.
Busulfan in fludarabin nimata nobene skupne poti presnove.
- 0.8 mg/kg body weight (BW) of busulfan as a two-hour infusion every 6 hours over 4 consecutive days for a total of 16 doses, - followed by cyclophosphamide at 60 mg/kg/day over 2 days initiated for at least 24 hours following the 16th dose of busulfan (see section 4.5).
- sledi ciklofosfamid 60 mg/kg/dan 2 dni, vsaj 24 ur po 16. odmerku busulfana (glejte poglavje
Viral infection CMV reactivation EBV reactivation Bacterial infection
Infekcijske in parazitske bolezni virusna okužba, reaktivacija CMV, reaktivacija EBV, bakterijska okužba invazivna glivična okužba, okužba pljuč možganski absces, celulitis, sepsa
the contents of the syringe must be dispensed into an intravenous bag (or syringe) which already contains the calculated amount of the selected diluent.
Z ne-polikarbonatno brizgo, na kateri je nameščena igla: - izračunan volumen zdravila Busulfan Fresenius Kabi morate odstraniti iz viale, - vsebino brizge morate prestaviti v vrečko (ali brizgo) za intravensko uporabo, v katero ste prej že dali izračunano količino izbranega redčila.
Read this guide prior to the preparation and administration of Busulfan Fresenius Kabi.
Pred pripravo in uporabo zdravila Busulfan Fresenius Kabi preberite to navodilo.
Mild/moderate fever was reported in 76% of patients.
Pri 76 % bolnikov so poročali o blago/zmerno povišani telesni temperaturi.
Medicinal product subject to restricted medical prescription.
DRUGI PODATKI Citotoksično zdravilo.
Musculoskeletal and connective tissue disorders
Bolezni mišičnoskeletnega sistema in vezivnega tkiva mialgija bolečina v hrbtu artralgija
Cerebral haemorrhage Encephalo-pathy
Bolezni živčevja glavobol omotica epileptični napad encefalopatija cerebralna hemoragija
Neutropenia Thrombocytopenia Febrile neutropenia Anaemia
Bolezni krvi in limfatičnega sistema nevtropenija trombocitopenija febrilna nevtropenija anemija
Transaminases increased Bilirubine increased Alkaline phosphatases increased
Preiskave povišane vrednosti transaminaz povišane vrednosti bilirubina povišane vrednosti GGT povišane vrednosti alkalnih fosfataz povečanje telesne mase neobičajni zvoki pri dihanju povišane vrednosti kreatinina povišan dušik sečnine v krvi zmanjšan iztisni delež prekata
Gastro-intestinal haemorrhage Tooth hypoplasia*
Bolezni sečil hemoragični cistitis** ledvična motnja oligurija
Tabulated lists of adverse reactions
Pregled neželenih učinkov v preglednici
Nervous system disorders
Priprava raztopine za infundiranje
Busulfan has not been studied in patients with hepatic impairment.
Pri bolnikih z okvaro jeter raziskav busulfana niso opravljali.
It may no longer be possible for you to achieve a pregnancy (infertility) after treatment with Busulfan Fresenius Kabi.
Po zdravljenju z zdravilom Busulfan Fresenius Kabi se lahko zgodi, da ne boste mogli več zanositi (neplodnost).
Oliguria
viala
Linearity
Viale
Nausea Vomiting Diarrhoea Stomatitis
Bolezni jeter, žolčnika in žolčevodov veno-okluzivna bolezen jeter zlatenica, bolezni jeter
Busulfan in combination with cyclophosphamide
Klinična učinkovitost in varnost Busulfan v kombinaciji s ciklofosfamidom Odrasli
Stomatitis Diarrhoea Abdominal pain Nausea
Bolezni jeter, žolčnika in žolčevodov hepatomegalija zlatenica veno-okluzivna jetrna bolezen*
This will help protect them against infectious bronchitis.
To jim bo pomagalo pri zaščiti pred kužnim bronhitisom.
In the future if the animals are exposed to the virus the immune system will be able to respond more quickly.
Ob ponovni izpostavitvi živali virusu v prihodnosti se bo imunski sistem tako hitreje odzval.
There are no precautions for the person, but it is recommended to wash and disinfect hands and equipment after vaccinating to avoid spread of the virus.
Previdnostnih ukrepov za ljudi ni, vendar je priporočljivo, da si oseba po dajanju cepiva umije in razkuži roke in pripomočke, da prepreči širjenje virusa.
In one trial, after three weeks 100% of chickens had developed antibodies to the IB 4-91 virus compared with 17% for the controls.
V enem preskušanju je po treh tednih 100 % piščancev razvilo protitelesa proti virusu IB 4-91 v primerjavi s 17 % v kontrolni skupini.
For prolonged immunity, chickens should be revaccinated every 6 weeks after the initial administration.
Za podaljšano imunost je treba cepljenje piščancev ponavljati vsakih šest tednov.
The main measures of effectiveness included the development of antibodies to the IB 4-91 virus, the overall death rate of the chickens and the percentage of chicken rejected because of disease.
Glavna merila učinkovitosti so bila razvoj protiteles proti virusu IB 4-91, celokupna stopnja smrtnosti piščancev in odstotek piščancev, zavrnjenih zaradi bolezni.
It is also the time allowed after administration of the medicine before eggs may be used for human consumption.
Pomeni tudi čas, ki mora preteči po dajanju zdravila, preden se lahko jajca uporabijo za prehrano ljudi.
The European Commission granted a marketing authorisation valid throughout the European Union for Nobilis IB 4-91 on 9 June 1998.
Evropska komisija je dovoljenje za promet z zdravilom Nobilis IB 4-91, veljavno po vsej Evropski uniji, izdala 9. junija 1998.
The vaccine virus may spread from vaccinated to non-vaccinated chickens, so care should be taken to separate vaccinated from non-vaccinated chickens.
Cepni virus se lahko razširi s cepljenih na necepljene piščance, zato je treba ti skupini piščancev ločiti.
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption.
Karenca je časovno obdobje, ki mora preteči po uporabi zdravila, preden se lahko žival zakolje ter meso uporabi za prehrano ljudi.
Avian infectious bronchitis vaccine (live attenuated)
cepivo proti kužnemu bronhitisu perutnine (živo, atenuirano)
The Nobilis IB 4-91 vaccine has been studied in various vaccination schedules in a number of trials.
Cepivo Nobilis IB 4-91 so proučevali v različnih shemah cepljenja v številnih preskušanjih.
Nobilis IB 4-91 can cause mild respiratory signs of disease which may last for a few days depending on the health and condition of the chickens.
Zdravilo Nobilis IB 4-91 lahko povzroči blage oblike znakov obolenja dihalnih poti, ki lahko trajajo nekaj dni, odvisno od zdravja in splošnega stanja piščancev.
Nobilis IB 4-91 vaccine has also been compared with controls, i.e. chickens that were not vaccinated.
Cepivo Nobilis IB 4-91 so primerjali tudi s kontrolno skupino, tj. s piščanci, ki niso bili cepljeni.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Nobilis IB 4-91 exceed the risks for the approved indication and recommended that Nobilis IB 4-91 should be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je zaključil, da so koristi zdravila Nobilis IB 4-91 večje od z njim povezanih tveganj, kadar se uporablja za odobrene indikacije, in priporočil, da se zanj izda dovoljenje za promet.
The vaccine was given by coarse spray to chicken of various ages.
Cepivo je bilo dajano z razpršilnikom z večjimi kapljicami piščancem različnih starosti.
The avian infectious bronchitis virus in Nobilis IB 4-91 has been attenuated (weakened) so that it does not cause disease.
Virus kužnega bronhitisa perutnine v cepivu Nobilis IB 4-91 je bil atenuiran (oslabljen), tako da ne povzroča bolezni.
Nobilis IB 4-91 is a vaccine.
Zdravilo Nobilis IB 4-91 je cepivo.
The vaccine can be administered to future layers and breeders from day old onwards via intranasal/ocular route or coarse spray.
Bodočim nesnicam in matičnim jatam se lahko cepivo daje od starosti enega dneva intranazalno/okularno ali z razpršilnikom z večjimi kapljicami.
Nobilis IB 4-91 can be given to 1-day-old chicks and older chickens by coarse spray or by intranasal (breathed in through the nose) or ocular (absorbed by the eyes) administration.
Zdravilo Nobilis IB 4-91 se lahko enodnevnim in starejšim piščancem daje z razpršilnikom z večjimi kapljicami, intranazalno (z vdihavanjem skozi nos) ali okularno (z absorpcijo skozi oči).
Nobilis IB 4-91 is used to immunise chickens to reduce the respiratory signs of infectious bronchitis caused by the variant strain IB 4-91, which causes infectious bronchitis in chickens.
Zdravilo Nobilis IB 4-91 se uporablja za imunizacijo piščancev z namenom zmanjšanja respiratornih znakov kužnega bronhitisa, ki ga povzroča različica seva IB 4-91, ki povzroča kužni bronhitis pri piščancih.
Other information about Nobilis IB 4-91:
Druge informacije o zdravilu Nobilis IB 4-91:
The vaccine can be given to 7-day and older chickens in their drinking water.
Piščancem, starejšim od sedem dni, se lahko cepivo daje v vodo za pitje.
When Nobilis IB 4-91 is given to chickens the animals' immune system recognises the virus as ‘foreign' and makes antibodies against it.
Ko piščance cepimo z zdravilom Nobilis IB 4-91, imunski sistem virus prepozna kot „tujek“ in proti njemu razvije protitelesa.
What benefit has Nobilis IB 4-91 shown during the studies?
Kakšne koristi je zdravilo Nobilis IB 4-91 izkazalo med študijami?